AT&T Inc.’s bid to have Makan Delrahim, head of the U.S. Department of Justice’s Antitrust Division, testify in the case challenging its planned purchase of Time Warner Inc., could help the company argue that the challenge was politically motivated, but it may not be easy and comes with some risk.
Howrey has continued the strategic expansion of its Brussels office with the addition of Martina Maier, the former head of the competition group at German law firm Haarmann Hemmelrath.
Another orthopedic device maker announced it has been subpoenaed by the U.S. Department of Justice, signaling the government could be conducting an industrywide probe into the $7 billion-a-year orthopedics industry.
As the battle over Cephalon Inc.’s narcolepsy drug Provigil continues to swell, generic drug maker Apotex has joined the fray, filing its own lawsuit accusing the pharmaceutical company and a slew of rival generic makers of barring competition by entering into a deal to delay introducing copycat versions of the drug.
All is not well for Hawaiian Airlines and inter-island competitor Mesa Air Group Inc., which have been slinging allegations of trade secret violations and anti-competitive conduct against each other in bankruptcy court.
The Boeing Company will pay $615 million to settle U.S. Department of Justice probes into allegations that Boeing illegally obtained and used competitors' information to win contracts worth billions of dollars from NASA and the Air Force.
A Chinese anti-monopoly law long sought by U.S. and European businesses failed to pass China’s parliament Thursday, placing it back into a seemingly endless limbo that began nearly 20 years ago when it was first introduced.
Echoing an earlier vote by the U.S. House of Representatives, a Senate committee rejected an amendment to block phone and cable companies from restricting access to their high-speed Internet networks by giving preferential treatment to Internet sites.
Marking a turn in the road for Mexico’s antitrust watchdog, the country’s revamped competition guidelines became law this week after months of deliberation by lawmakers and lobbyists.
The first class action was filed against BP Products North America just one day after a former trader at the U.S. unit pled guilty to partaking in a scheme to manipulate the propane market.
The Washington utility company that helped uncover an Enron Corp. conspiracy to manipulate energy markets will not have to pay Enron a $120 million contract termination fee, federal regulators have determined.
In the wake of a new study lauding the competitive effects of authorized generics, the Generic Pharmaceutical Association has issued a blistering statement calling into question the reliability of the report.
The European Commission proposed new regulations Thursday to promote competition in the telecommunications industry, inciting anxiety among telecom giants less than a week after E.C. director Neelie Kroes warned of a possible probe of the $338 billion industry.
Brand-name drug manufacturers, facing potentially billions of dollars in losses when their patent protection on drugs expires, are attempting to protect their market shares by slashing prices to undercut the generic competition--a move that has some accusing the pharmaceutical companies of predatory pricing.
Two U.S. vehicle auctioneers have resolved a dispute over patent infringement allegations fueled by an online auction system and alleged antitrust violations in the vehicle auction market.
The Senate Judiciary Committee plans to dive into a heated debate over credit card interchange rates and potential antitrust concerns at an upcoming hearing.
In a decision that could affect future white collar cases, a district court judge in Manhattan ruled Tuesday that the government violated the constitutional rights of former KPMG LLP partners by pressuring the firm to not pay their legal fees.
A federal court in Washington, D.C. will decide whether or not to approve the settlements that paved the way for the AT&T/SBC and MCI/Verizon mergers in a hearing scheduled for next month.
Four top Senate judiciary committee members are taking matters into their own hands and introducing legislation to prohibit brand-name drug makers from paying rivals to keep generic drugs off the market.
Rallying against lawmakers, the U.S. Department of Justice’s Antitrust Division and the Federal Trade Commission this week lashed out against proposed legislation that seeks to curb non-lawyers from competing with licensed attorneys in the real estate industry in New York state, saying the move is not in the best interest of consumers.
The European Commission’s antitrust commissioner has confirmed that harsh new penalties are on the horizon for companies that violate the continent’s competition laws, and provided details about how new procedural changes will make that happen.